News
Pharmaceutical Technology on MSN6d
MSD receives FDA approval for Enflonsia to prevent RSVMSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...
Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...
Zacks.com on MSN6d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in InfantsMRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...
Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...
CHARLOTTE — Whitney Hamilton says her 4-year-old son, Elijah, is always happy, but his life dramatically changed in February ...
Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.
Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback